Roche Steps Closer To Flu Market Domination With Phase III Baloxavir Results

Not even a month after the FDA granted the antiviral Priority Review, baloxavir marboxil has shown superior efficacy in its primary endpoint in the latest CAPSTONE-2 Phase III clinical study, taking it closer to possible market supremacy for influenza A and B.